Tuesday September 1, 8:43 am Eastern Time
Company Press Release
SOURCE: Biomerica, Inc.
Biomerica Introduces New Thyroid
Disease Test Worldwide & Seeks U.S. FDA Clearance
NEWPORT BEACH, Calif., Sept. 1 /PRNewswire/ -- Biomerica, Inc. (Nasdaq: BMRA - news)
announced today that it has filed for clearance with the U.S. Food and Drug Administration to
market its new free T4 enzyme immunoassay test. The Company also announced that it has launched
its free T4 EIA kit internationally. The estimated worldwide market for all thyroid testing is
approximately $600 million.
The new non-radioactive enzyme based product determines the amount of free thyroxin (T4)
circulating in the bloodstream. This is a significant aid in the assessment of thyroid function. Free T4
is one of the two major thyroid tests used in most clinical situations.
The free T4 EIA kit would complete the Company's line of thyroid endocrinology tests. Biomerica
currently has five tests to determine thyroid disease and thyroid dysfunction that have been cleared to
market by the FDA.
Biomerica's new product does not employ radioactivity, thereby simplifying the handling of the test
and eliminating radioactive waste. Utilizing a simple microwell format, capable of running 45 patient
samples at one time, the new test is easily automated, highly accurate and cost effective. Biomerica's
panel of thyroid tests is a key aid to determining the presence of, and monitoring for, Graves'
disease, Hashimoto's thyroiditis and primary thyroid failure.
Biomerica (Nasdaq: BMRA - news) is a global medical company devoted to developing,
manufacturing and marketing advanced medical diagnostic products for the early detection of
diseases. The products are used in hospitals, physician's offices and in the home for self testing.
Except for historical information contained herein, the statements in this Press Release are
forward-looking statements that are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform act of 1995. Forward-looking statements may involve known and
unknown risks and uncertainties which may cause the Company's actual results in future periods to
differ materially from forecasted results. These risks and uncertainties include, among other things,
the continued demand for the Company's products, availability of raw materials and the state the
economy. These and other risks are described in the Company's Annual Report on Form 10-KSB
and in the Company's other filings with the Securities and Exchange Commission.
SOURCE: Biomerica, Inc.
|
